News & ViewsNewslettersContactBecome a Research Patient
DHRHealth Institute for Research and Development

Clinical Trial

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)

Study Status:

Closed for enrollment

Contact Information:

(956) 362-8047

Please contact us for more information or to learn if you are eligible to participate.

Study Purpose:

To evaluate the effect of EFX compared to placebo on fibrosisregression in subjects with compensated cirrhosis due to NASH at Week 36

Information: 

Principal Investigator
Fernando Membreno, MD
Co-PI
Guillermo Duran
Sponsor
Akero Therapeutics, Inc.
Type of Trial
Interventional
© 2023 DHR Health Institute for Research & Development | All Rights Reserved | Terms & Conditions | Site By: KangoMedia
chevron-down linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram